Phenyl aminosalicylate
Pheny-pas-tebamin (phenyl aminosalicylate) is a small molecule pharmaceutical. Phenyl aminosalicylate was first approved as Pheny-pas-tebamin on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Phenyl aminosalicylate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PHENY-PAS-TEBAMIN | Pharmaceutical Research Associates Inc | N-011695 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dental anesthesia | D000766 | — | 1 | 2 | 1 | — | 4 | ||
| Local anesthesia | D000772 | — | — | — | 2 | 1 | 3 | ||
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | — | 1 | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 | |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | — | 1 | — | — | — | 1 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 1 | — | — | — | 1 |
| Hypesthesia | D006987 | HP_0003474 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | — | — | — | — | 3 |
| Vasodilation | D014664 | 2 | — | — | — | 1 | 3 | ||
| Healthy volunteers/patients | — | 3 | — | — | — | — | 3 | ||
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | — | — | 1 | 2 |
| Vasoconstriction | D014661 | 1 | — | — | — | 1 | 2 | ||
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | 1 | — | — | — | — | 1 | ||
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
| Stem cell transplantation | D033581 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Cerebral hemorrhage | D002543 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PHENYL AMINOSALICYLATE |
| INN | fenamisal |
| Description | 4-amino-2-hydroxybenzoic acid phenyl ester is a carbonyl compound. |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (salicylic acid derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccc(C(=O)Oc2ccccc2)c(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 133-11-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200868 |
| ChEBI ID | — |
| PubChem CID | 8609 |
| DrugBank | — |
| UNII ID | 52936SIP7V (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
138 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more